Literature DB >> 33853888

Could NAD+ Precursor Supplements Induce a Legacy of Protection against Diabetic Nephropathy?

Kelly A Hyndman1, Matthew D Griffin2,3.   

Abstract

Entities:  

Keywords:  NAD metabolism; diabetic nephropathy; epigenetics; sirtuin

Mesh：

Substances：

Year:  2021        PMID： 33853888      PMCID： PMC8259642          DOI： 10.1681/ASN.2021020275

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   14.978


× No keyword cloud information.
  10 in total

1.  Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.

Authors:  Kathryn F Mills; Shohei Yoshida; Liana R Stein; Alessia Grozio; Shunsuke Kubota; Yo Sasaki; Philip Redpath; Marie E Migaud; Rajendra S Apte; Koji Uchida; Jun Yoshino; Shin-Ichiro Imai
Journal:  Cell Metab       Date:  2016-10-27       Impact factor: 27.287

Review 2.  Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.

Authors:  Milton Packer
Journal:  J Am Soc Nephrol       Date:  2020-04-10       Impact factor: 10.121

Review 3.  Sirtuins in Renal Health and Disease.

Authors:  Marina Morigi; Luca Perico; Ariela Benigni
Journal:  J Am Soc Nephrol       Date:  2018-04-30       Impact factor: 10.121

4.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Authors:  N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda
Journal:  Diabetes Res Clin Pract       Date:  2018-02-26       Impact factor: 5.602

Review 5.  NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.

Authors:  Jun Yoshino; Joseph A Baur; Shin-Ichiro Imai
Journal:  Cell Metab       Date:  2017-12-14       Impact factor: 27.287

6.  Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes.

Authors:  Kazuhiro Hasegawa; Shu Wakino; Petra Simic; Yusuke Sakamaki; Hitoshi Minakuchi; Keiko Fujimura; Kozi Hosoya; Motoaki Komatsu; Yuka Kaneko; Takeshi Kanda; Eiji Kubota; Hirobumi Tokuyama; Koichi Hayashi; Leonard Guarente; Hiroshi Itoh
Journal:  Nat Med       Date:  2013-10-20       Impact factor: 53.440

7.  A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.

Authors:  Ole L Dollerup; Britt Christensen; Mads Svart; Mark S Schmidt; Karolina Sulek; Steffen Ringgaard; Hans Stødkilde-Jørgensen; Niels Møller; Charles Brenner; Jonas T Treebak; Niels Jessen
Journal:  Am J Clin Nutr       Date:  2018-08-01       Impact factor: 7.045

8.  Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.

Authors:  Junichiro Irie; Emi Inagaki; Masataka Fujita; Hideaki Nakaya; Masanori Mitsuishi; Shintaro Yamaguchi; Kazuya Yamashita; Shuhei Shigaki; Takashi Ono; Hideo Yukioka; Hideyuki Okano; Yo-Ichi Nabeshima; Shin-Ichiro Imai; Masato Yasui; Kazuo Tsubota; Hiroshi Itoh
Journal:  Endocr J       Date:  2019-11-02       Impact factor: 2.349

9.  Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy.

Authors:  Itaru Yasuda; Kazuhiro Hasegawa; Yusuke Sakamaki; Hirokazu Muraoka; Takahisa Kawaguchi; Ei Kusahana; Takashi Ono; Takeshi Kanda; Hirobumi Tokuyama; Shu Wakino; Hiroshi Itoh
Journal:  J Am Soc Nephrol       Date:  2021-04-01       Impact factor: 14.978

Review 10.  SIRT1 Is a Potential Drug Target for Treatment of Diabetic Kidney Disease.

Authors:  Yifei Zhong; Kyung Lee; John Cijiang He
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-17       Impact factor: 5.555
  10 in total
  1 in total

1.  SIRT6 overexpression retards renal interstitial fibrosis through targeting HIPK2 in chronic kidney disease.

Authors:  Xiaoxue Li; Wenxin Li; Zhengzhipeng Zhang; Weidong Wang; Hui Huang
Journal:  Front Pharmacol       Date:  2022-09-12       Impact factor: 5.988
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.